Nutriband inc. reports revenue up 46% in fiscal 2023

Orlando, fl / accesswire / april 27, 2023 / nutriband inc. (nasdaq:ntrb) (nasdaq:ntrbw), a developer of transdermal pharmaceutical products, today announced financial and operational results for the fiscal year ended january 31, 2023. key highlights: generated record revenue of $2.1 million, up 46% over the prior fiscal year successfully obtained court verdict for recovery of shares constituting 15% of its total outstanding shares announced a seven-for-six forward stock split to reward shareholders following the successful court verdict received notice of allowance from the canadian intellectual property office for aversa™ patent completing patent issuance in all of north america demonstrated with kindeva drug delivery enhanced abuse-deterrent characteristics for aversa™ fentanyl announced plans to officially launch ai tape brand in q1 of 2023 company coo, alan smith ph.d selected for fda centre for research on complex generics expert committee with kindeva drug delivery, selected aversa™ fentanyl abuse deterrent formulation for commercial scale manufacturing process development "our 2022 results and milestones have shown that we remain laser focused on hitting the targets we set ourselves as a company each year.
NTRB Ratings Summary
NTRB Quant Ranking